Table 2 Overview of treatment protocol and associated clinical course.

From: Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma

Characteristic

N = 101

CRS events — no. (%)

 Any grade

76 (75%)

 Grade 1

34 (34%)

 Grade 2

34 (34%)

 Grade ≥3

8 (8%)

Median time to CRS onset (range) — d

1 (0–14)

Median duration of CRS (range) — d

3 (0–10)

ICANS events — no. (%)

 Any grade

14 (14%)

 Grade 1

8 (8%)

 Grade 2

4 (4%)

 Grade ≥3

2 (2%)

Median time to ICANS onset (range) — d

3.5 (0–29)

Median duration of ICANS (range) — d

5 (0–35)

TCZ use within 30 days post-infusion — no. (%)

49 (49%)

Median time to first TCZ dose (range) — d

1 (0–18)

Median duration of TCZ course (range) — d

0 (0–2)

CCS use within 30 days post-infusion — no. (%)

34 (34%)

Median time to first CCS dose (range) — d

2 (0–41)

Median duration of CCS course (range) — d

1 (0–52)

Median cumulative DexEq dose (range)a — mg

20 (10–580)

Use of other immunosuppressants — no. (%)

 Siltuximabb

2 (2%)

 Anakinrac

5 (5%)

  1. CCS corticosteroid, CRS cytokine release syndrome, DexEq dexamethasone-equivalent, ICANS immune effector cell-associated neurotoxicity syndrome, TCZ tocilizumab.
  2. aCalculated among patients who received CCS within 30 days of CAR T-cell infusion (n = 34).
  3. bAnti-interleukin-6 chimeric monoclonal antibody.
  4. cRecombinant human interleukin-1 receptor antagonist.
Back to article page